文献速递胸部肿瘤放疗

治疗前中性粒细胞-淋巴细胞比值对局限性非小细胞肺癌立体定向放疗生存结局的预后价值:理想临床界值的选取

Prognostic utility of pretreatment neutrophil-lymphocyte ratio in survival outcomes in localized non-small cell lung cancer patients treated with stereotactic body radiotherapy: Selection of an ideal clinical cutoff point.
PubMed 文献 · Clin Transl Radiat Oncol · 2021-04-07

该回顾性队列研究基于美国退伍军人事务部(VA)全国数据库,纳入2006至2015年间接受立体定向体部放疗(SBRT)的389例活检证实、临床I期非小细胞肺癌(NSCLC)患者,采用Contal/O'Quigley法与Cox Wald法确定治疗前中性粒细胞-淋巴细胞比值(NLR)的最佳界值为4.0。多因素分析显示NLR>4.0与总生存(OS)及非肺癌生存(NCS)下降相关,但与肺癌特异性生存(LCS)无关,提示治疗前NLR可作为竞争性死亡风险的标志物,辅助该虚弱合并症人群的风险分层。

要点

  • 在389例接受SBRT的I期NSCLC患者中,治疗前NLR最佳界值为4.0。
  • NLR>4.0与OS(HR 1.44,p=0.01)和NCS(HR 1.68,p=0.01)下降相关,但与LCS无关(HR 1.32,p=0.09)。
  • NLR>4.0可能反映竞争性死亡风险,有助于该虚弱合并症人群的风险分层。

核心结论

  • 在局限性NSCLC接受SBRT的患者中,治疗前NLR>4.0与更差的总生存和非肺癌生存相关,但与肺癌特异性生存无关。
  • 治疗前NLR(界值4.0)有潜力作为竞争性死亡风险的标志物,辅助该虚弱合并症人群的风险分层。

研究设计与样本

  • 回顾性队列研究,基于美国退伍军人事务部(VA)全国数据库,纳入2006至2015年间活检证实、临床I期NSCLC并接受SBRT的患者389例。
  • 采用Contal/O'Quigley法和Cox Wald法计算NLR界值,主要结局OS、LCS和NCS采用Cox和Fine-Gray模型评估。
  • 亚组分析纳入229例有肺功能检查的患者。

主要发现

  • 在389例患者中,治疗前NLR最佳界值为4.0。
  • 多因素模型中,NLR>4.0与OS下降相关(HR 1.44,p=0.01),与NCS下降相关(HR 1.68,p=0.01),但与LCS无关(HR 1.32,p=0.09)。
  • 在229例有肺功能检查的亚组中,NLR>4.0仍与更差OS相关(HR 1.51,p=0.02)和更差NCS相关(HR 2.18,p=0.01),与LCS的关联进一步减弱(HR 1.22,p=0.39)。

关键数值与推荐

  • 治疗前NLR最佳界值为4.0(基于Contal/O'Quigley法和Cox Wald法)。
  • NLR>4.0与OS下降相关:HR 1.44,p=0.01(多因素模型,n=389)。
  • NLR>4.0与NCS下降相关:HR 1.68,p=0.01(多因素模型,n=389)。
  • NLR>4.0与LCS无关:HR 1.32,p=0.09(多因素模型,n=389)。

临床怎么用

  • 对于接受SBRT的局限性NSCLC患者,治疗前可考虑计算NLR,以4.0为界值识别竞争性死亡风险较高的患者。
  • NLR>4.0提示总生存和非肺癌生存较差,可能有助于在该虚弱合并症人群中优化风险分层和临床决策。
  • NLR与肺癌特异性生存无关,因此不宜单独作为肺癌特异性预后指标使用。

局限性

  • 研究为回顾性数据库分析,可能存在选择偏倚和未测量混杂因素。
  • 亚组分析仅纳入229例有肺功能检查的患者,样本量有限。
  • 作者指出需要进一步研究验证治疗前NLR作为临床工具的价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Neutrophil-lymphocyte ratio (NLR) has been associated with overall survival (OS) in non-small cell lung cancer (NSCLC). We aimed to assess the utility of NLR as a predictor of lung cancer-specific survival (LCS) and identify an optimal, pretreatment cutoff point in patients with localized NSCLC treated with stereotactic body radiotherapy (SBRT) within the Veterans Affairs' (VA) national database. MATERIALS AND METHODS: In the VA database, we identified patients with biopsy-proven, clinical stage I NSCLC treated with SBRT between 2006 and 2015. Cutoff points for NLR were calculated using Contal/O'Quigley's and Cox Wald methods. Primary outcomes of OS, LCS, and non-lung cancer survival (NCS) were evaluated in Cox and Fine-Gray models. RESULTS: In 389 patients, optimal NLR cutoff was identified as 4.0. In multivariable models, NLR > 4.0 was associated with decreased OS (HR 1.44, p = 0.01) and NCS (HR 1.68, p = 0.01) but not with LCS (HR 1.32, p = 0.09). In a subset analysis of 229 patients with pulmonary function tests, NLR > 4.0 remained associated with worse OS (HR 1.51, p = 0.02) and NCS (HR 2.18, p = 0.01) while the association with LCS decreased further (HR 1.22, p = 0.39). CONCLUSION: NLR was associated with worse OS in patients with localized NSCLC treated with SBRT; however, NLR was only associated with NCS and not with LCS. Pretreatment NLR, with a cutoff of 4.0, offers potential as a marker of competing mortality risk which can aid in risk stratification in this typically frail and comorbid population. Further studies are needed to validate pretreatment NLR as a clinical tool in this setting.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kotha NV, Cherry DR, Bryant AK, et al. Prognostic utility of pretreatment neutrophil-lymphocyte ratio in survival outcomes in localized non-small cell lung cancer patients treated with stereotactic body radiotherapy: Selection of an ideal clinical cutoff point. Clin Transl Radiat Oncol. 2021. PMID: 33997320. doi:10.1016/j.ctro.2021.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。